Ameritas Advisory Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ameritas Advisory Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-34	Closed	-$1.84K	–	1061
2025 Q3	$1.84K	Hold	34	–	–	﹤0.01%	1999
2025 Q2	$1.87K	Buy	+34	New	+$2K	﹤0.01%	2493
2023 Q2	–	Sell	-13	Closed	-$1.25K	–	775
2023 Q1	$1.25K	Buy	+13	New	+$1.35K	﹤0.01%	2508

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameritas Advisory Services's BMRN Position: Q4 2025 in Review

Ameritas Advisory Services sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 34 shares — an estimated $1.84K sold.

Ameritas Advisory Services first reported a position in BMRN in Q1 2023 and held it in 3 quarters. The position peaked at $1.87K in Q2 2025. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Ameritas Advisory Services reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Ameritas Advisory Services sold 34 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $1.84K.
Ameritas Advisory Services first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 3 quarters.
Ameritas Advisory Services's BioMarin Pharmaceuticals position peaked at $1.87K in Q2 2025.
538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Ameritas Advisory Services's 13F filing for Q4 2025, filed 4 Feb 2026.